Piramal
knowledge action care

PIRAMAL ENTERPRISES LIMITED

Piramal Tower, Peninsula Corporate Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013.

STATEMENT OF STANDALONE AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2015

PART I

(Rs. in Lakhs)

Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Previous Year ended
	31/03/2015 (Unaudited)	31/12/2014 (Unaudited)	31/03/2014 (Unaudited)	31/03/2015 (Audited)	31/03/2014 (Audited)
Income from operations					
Net Sales / Income from Operations (Net of excise duty)	65,940	64,834	47,778	227,973	181,347
Other Operating Income	1,062	1,017	4,893	12,168	17,705
Total Income from Operations, Net	**67,002**	**65,851**	**52,671**	**240,141**	**199,052**
Expenses					
Cost of Materials Consumed	21,782	22,947	19,451	79,780	70,064
Purchase of Stock-in-Trade	1,777	1,706	1,961	8,024	8,497
Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,417	(2,476)	(1,444)	(515)	(3,771)
Employee benefits expense	9,192	6,379	4,962	27,713	21,350
Depreciation and amortisation expense (Refer Note 5)	1,913	2,534	1,917	8,884	7,622
Research and Development Expenses	2,502	2,858	5,285	18,312	24,012
Other Expenses, Net	16,875	18,253	18,733	62,361	57,762
Total Expenses	**56,458**	**52,201**	**50,865**	**204,559**	**185,536**
Profit / (Loss) from operations before other income, finance costs and exceptional items	**10,544**	**13,650**	**1,806**	**35,582**	**13,516**
Other Income (Refer Note 4)	4,000	8,466	639	29,859	28,942
Profit / (Loss) from ordinary activities before finance costs and exceptional items	**14,544**	**22,116**	**2,445**	**65,441**	**42,458**
Finance Costs	8,231	6,237	22,584	30,691	81,258
Profit / (Loss) from ordinary activities after finance costs but before exceptional items	**6,313**	**15,879**	**(20,139)**	**34,750**	**(38,800)**
Exceptional Income/ (Expense), net (Refer Note 6)	2,543	(239,108)	-	29,888	1,800
Profit / (Loss) from ordinary activities before tax	**8,856**	**(223,229)**	**(20,139)**	**64,638**	**(37,000)**
Tax Expense (Refer Note 10)	1,587	601	-	27,364	-
Net Profit / (Loss) from ordinary activities after tax	**7,269**	**(223,830)**	**(20,139)**	**37,274**	**(37,000)**
Extraordinary Items (net of tax expense)	-	-	-	-	-
Net Profit / (Loss) for the period	**7,269**	**(223,830)**	**(20,139)**	**37,274**	**(37,000)**
Paid-up Equity Share Capital (Face Value Rs.2/- each)	3,451	3,451	3,451	3,451	3,451
Paid-up Debt Capital				85,000	35,000
Reserves (Excluding Revaluation Reserves)				1,141,233	909,257
Debenture Redemption Reserve				8,542	3,000
Earnings Per Share (EPS) (of Rs.2/- each)					
a) Basic and diluted EPS before extraordinary items for the period (Rs.)	4.2	(129.7)	(11.6)	21.6	(21.4)
b) Basic and diluted EPS after extraordinary items for the period (Rs.)	4.2	(129.7)	(11.6)	21.6	(21.4)
Debt Equity Ratio				0.3	0.6
Debt Service Coverage Ratio (Refer Footnote No. 1)				4.0	0.9
Interest Service Coverage Ratio (Refer Footnote No. 2)				2.1	0.4

Footnotes:

1. Debt Service Coverage Ratio = Earnings before Interest and Tax/ (Interest Expense + Principal Repayment)
   Debt = Long Term Debt
   Interest Expense = Interest on Long Term Debt
2. Interest Service Coverage Ratio = Earnings before Interest and Tax / Interest Expense

PART II

A. PARTICULARS OF SHAREHOLDING					
1. Public Shareholding					
- Number of shares	81,370,027	81,339,596	81,201,342	81,370,027	81,201,342
- Percentage of shareholding	47.15%	47.14%	47.06%	47.15%	47.06%
2. Promoters and Promoter group Shareholding					
a) Pledged/Encumbered					
- Number of shares	-	-	-	-	-
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-
b) Non-encumbered					
- Number of Shares	91,193,073	91,223,504	91,361,758	91,193,073	91,361,758
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	52.85%	52.86%	52.94%	52.85%	52.94%

Particulars	3 months ended 31/03/2015
B. INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	1
Received during the quarter	6
Disposed of during the quarter	6
Remaining unresolved at the end of the quarter	1

PIRAMAL ENTERPRISES LIMITED MUMBAI

Piramal
knowledge action care

Notes:

1. The standalone financial results, for the quarter and year ended March 31, 2015, have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 6, 2015 and May 7, 2015 respectively.

2. **Statement of Assets and Liabilities:**
   Disclosure of Balance sheet items as per Clause 41(V)(h) of the Listing Agreement as at March 31, 2015:

(Rs.in Lakhs)

Particulars	As at	
	31/03/2015 (Audited)	31/03/2014 (Audited)
EQUITY AND LIABILITIES		
Shareholders' Funds		
Share Capital	3,451	3,451
Reserves and Surplus	1,141,233	909,257
Sub-total Shareholders' funds	**1,144,684**	**912,708**
Non-Current Liabilities		
Long-Term Borrowings	119,501	65,334
Deferred Tax Liabilities, Net	-	-
Other Long-term Liabilities	71	2,342
Long Term Provisions	9,679	5,594
Sub-total Non-current Liabilities	**129,251**	**73,270**
Current Liabilities		
Short Term Borrowings	260,830	515,978
Trade Payables	27,269	24,672
Other Current Liabilities	31,047	57,806
Short Term Provisions	50,177	108,430
Sub-total Current Liabilities	**369,323**	**706,886**
TOTAL EQUITY AND LIABILITIES	**1,643,258**	**1,692,864**
ASSETS		
Non-current Assets		
Fixed Assets	81,750	94,255
Non-Current Investments	929,475	1,148,487
Long-term Loans and Advances	104,819	67,399
Other Non-Current Assets	17,701	15,724
Sub-total Non-Current Assets	**1,133,745**	**1,325,865**
Current Assets		
Current Investments	92,793	10,129
Inventories	32,108	30,049
Trade Receivables	32,759	25,627
Cash and Bank Balances	4,039	3,185
Short Term Loans and Advances	342,799	219,389
Other Current Assets	5,015	78,620
Sub-total Current Assets	**509,513**	**366,999**
TOTAL ASSETS	**1,643,258**	**1,692,864**

PIRAMAL ENTERPRISES LIMITED MUMBAI

Piramal
knowledge action care

3. In accordance with Accounting Standard 17 'Segment Reporting', segment information has been given in the consolidated financial results of Piramal Enterprises Limited, and therefore, no separate disclosure on segment information is given in these standalone results.

4. Other Income includes the effect of Foreign Exchange Gain / (Loss), Net incurred during the respective periods.

(Rs. in Lakhs)

	Quarter Ended	Quarter Ended	Quarter Ended	Year ended	Previous Year ended
	31/03/2015	31/12/2014	31/03/2014	31/03/2015	31/03/2014
Exchange Gain / (Loss), Net	(2,465)	2,407	(1,350)	4,841	17,929

5. The Company revised depreciation rates on tangible fixed assets w.e.f. April 01, 2014 as per the useful life specified in the Schedule II of the Companies Act, 2013 or as re-assessed by the Company. As prescribed in said Schedule II, an amount of Rs.765 Lakhs (net of deferred tax) has been charged to the opening balance of retained earnings for the assets in respect of which the remaining useful life is NIL as on April 01, 2014 and in respect of other assets on that date, depreciation has been calculated based on the remaining useful life of those assets. Had the Company continued with the previously applicable Schedule XIV rates, charge for depreciation for the quarter and year ended March 31, 2015 would have been lower and the net profit would have been higher by Rs 131 Lakhs and Rs. 1,058 Lakhs respectively.

6. Exceptional Income/Expense, net includes :
   i. gain on sale of Investment in Vodafone India Limited during the quarter and year ended March 31, 2015, Rs. Nil and Rs.303,608 lakhs respectively;
   ii. gain on sale of the Lab Diagnostics and Point of Care business to Diasys Diagnostics India Private Limited during the quarter and year ended March 31, 2015, Rs. Nil and Rs.260 lakhs respectively;
   iii. costs and write downs / (writeback) on account of scaling down the Research and development activities of the New Chemical Entity (NCE) division for the quarter, preceding quarter and year ended March 31, 2015 (Rs.4,000 lakhs), (Rs.3,470 lakhs) and Rs. 29,945 lakhs respectively;
   iv. recovery of License Fee written off in earlier periods for the quarter, year ended March 31, 2015 and year ended March 31, 2014, Rs. Nil, Rs. Nil and Rs. 1,800 lakhs respectively;
   v. The Scheme of Amalgamation ("the Scheme") of Oxygen Bio Research Private Limited ("O2H"), Piramal Pharmaceutical Development Services Private Limited ("PPDSPL") and PHL Capital Private Limited ("PHL Capital") (collectively referred to as "transferor companies") with Piramal Enterprises Limited ("the Company"), under Sections 391 to 394 of the Companies Act, 1956 was sanctioned by the Hon'ble High Courts of Gujarat and Bombay on November 11, 2014 and November 28, 2014 respectively. The Scheme became effective on December 12, 2014 and December 27, 2014 upon filing of the said orders with the Registrar of Companies, Gujarat and Maharashtra respectively. The Scheme has accordingly been given effect to in these results.
   Consequently, all the assets and liabilities of transferor companies have been transferred to and vested in the Company with effect from April 01, 2014 ("the Appointed Date"). Since the appointed date, Revenue of Rs. 2,003 lakhs, 8,734 lakhs, and Rs.10,737 lakhs and profit before taxes of Rs.197 lakhs, Rs.2,771 lakhs and Rs.2,968 lakhs pertaining to the above transferor companies are included under respective heads in the results for the current quarter, preceding quarter and year ended March 31, 2015 respectively.
   The amalgamation has been accounted for under the "pooling of interest" method referred to in Accounting Standard 14 - Accounting for Amalgamation, as prescribed by the Scheme. Accordingly, all the assets, liabilities and other reserves of transferor companies as on April 01, 2014 have been aggregated with those of the Company at their respective book values. As prescribed by the Scheme, no consideration was paid as the transferor Companies were wholly owned step down subsidiaries of the Company, hence the resultant difference amounting to Rs. 233,914 lakhs has been credited to capital reserve account. Consequent to the scheme of amalgamation, the company has sold its investment in the intervening holding company of the transferor companies, the difference between sales consideration and the cost of investment amounting to Rs. 242,328 lakhs has been accordingly recognised and disclosed under Exceptional Expenses; and
   vi. Costs associated with write-down of Tangible / Intangible Assets during the quarter and year ended March 31, 2015, Rs.1,707 lakhs.

7. A Dividend of Rs.20 per equity share (1000% of the face value of Rs.2/- each) has been recommended by the Board of Directors which is subject to approval of the Shareholders.

8. Subsequent to the year-end :
   a) The Company signed a definitive agreement to sell its clinical research business known as 'Piramal Clinical Research (PCR)' (formerly known as Wellquest), to Indoco Remedies Limited (Indoco) on a going concern basis. Fixed assets of this division along with the employees were transferred to Indoco on a slump sale basis as a part of the transaction for a consideration of Rs.464 lakhs. The transaction does not have a material impact on the Company's results or financial position; and
   b) the Company has invested Rs.60 lakhs for a minority stake in Health SuperHiway Private Limited ("HealthHiway"), a healthcare analytics company. The company has committed to invest an additional amount of Rs. 4,420 lakhs subject to achievement of certain milestones by HealthHiway. Upon the second tranche of investment, the Company will control a majority stake in the business, on a fully diluted basis.

9. The figures for the last quarter are balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the current financial year.

10. Tax expense comprises of Current tax (including prior period tax) and Deferred Tax and is net of MAT credit entitlement.

11. Previous period / year's figures have been regrouped / reclassified wherever necessary to correspond with the current period's classification. The figures for the quarter and year ended March 31, 2015 are not comparable to the previous quarter and year ended March 31, 2014 on account of the merger as referred in note 6 (v).

For **PIRAMAL ENTERPRISES LIMITED**

Ajay G. Piramal
Chairman

May 7, 2015, Mumbai.